Ambinder R, Mann R. Epstein-Barr encoded RNA in situ hybridization. Hum Pathol 1994;25:602.
Aygun B, Karakas SP, Leonidas J, Valderrama E, and Karayalcin G. Reliability of splenic index to assess splenic involvement in pediatric Hodgkin's disease. J Pediatr Hematol Oncol 2004;26:74.
Bonadonna G, Valagussa P, Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease: a report of 8-year results. Ann Intern Med 1986;104:746.
Carbone PP, Kaplan HS, Husshoff K, et al. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971;31:1860.
De Vita VTJ, Canellos G, Moxley J. A decade of combination chemotherapy of advanced Hodgkin's disease. Cancer 1972;30:1495.
Donaldson SS, Hudson M, Lamborn R, et al. VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin disease: results of a prospective trial. J Clin Oncol 2002;20:3081.
Harris NL, Jaffe ES, Diebold J, et al. Wood Health Organization classification of neo-plastic diseases of hemapoietic and lymphoid tissues: report of the clinical of neo-plastic diseases of hemapoietic and lymphoid tissues. Report of the Clinical Advisory Committee Meeting, Virginia, Airlie House, November 1997. JCO 1999;17:3835.
Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361.
Kadin ME, Liebowitz. Cytokines and cytokine receptors in Hodgkin's disease. In: Mauch PM, Armitrage J, Diehl V, Hoppe RT, Weiss LM, editors. Hodgkin's Disease. Philadelphia: Lippincott Williams & Wilkins, 1999;139-57.
Karayalcin G, Behm FG, Geiser PW, et al. Lymphocyte predominant Hodgkin's disease; clinicopathologic features and results of treatment—the Pediatric Oncology Group experience. Med Pediatr Oncol 1997;29:516.
Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin's disease. Cancer Res. 1966;26:1063.
Nachman JB, Sposo R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002;20:3765.
Rini JN, Manalili EY, Hoffman M, Karayalcin G, Mechatra B, Thomas B, Palestro CJ. F-18 FDG versus Ga-67 for detecting splenic involvement in Hodgkin's disease. Clin Nucl Med 2002;27:572.
Ruhl U, Albrecht M, Dieckmann K, et al. Response-adapted radiotherapy in the treatment of pediatric Hodgkin's disease: an interim report at 5 years of the German GPOH-HD 95 trial. Int J Radiat Oncol Bio Phys 2001;51:1209.
Schellong G. Treatment of children and adolescents with Hodgkin's disease: the experience of the German-Austrian Paediatric Study Group. Baillieres Clin Haemotol 1996;9:619.
Schmitz N, Pfister B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous stem-cell transplantation for relapsed chemo-sensitive Hodgkin's disease. A randomized trial. Lancet 2002;341:1051.
Stein H, Diehl V, Marafieti T, et al. The nature of Reed-Sternberg cells, lymphocytic and histiocytic cells and their molecular biology in Hodgkin's disease. In: Mauch PM, Armitage J, Diehl V, Hoppe RT, Weiss LM, editors. Hodgkin's Disease. Philadelphia: Lippincott Williams & Wilkins, 1999;121-37.
Weiner MA, Leventhal BG, Marcus R, et al. Intensive chemotherapy and low-dose radiotherapy for the treatment of advanced-stage Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. J Clin Oncol 1991;9:1591.
Was this article helpful?
Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.